Schilddrüsenkarzinome

  • C. Reiners
  • M. Stuschke

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Robbins J, Merino MJ, Boice JD Jr, Ron E, Ain KB, Alexander HR, Norton JA, Reynolds J (1991) Thyroid cancer: a lethal endocrine neoplasm. Ann Intern Med 115:133–147PubMedCrossRefGoogle Scholar
  2. 2.
    Reiners Chr (1993) Besondere Risikofaktoren der Struma maligna. In: Struma maligna. Derzeitiger Stand in Diagnose und Therapie (Hrsg) Pimpl W, Galvan G, Kogelnik HD et al. Springer-Verlag, Berlin Heidelberg New York: p 12–20CrossRefGoogle Scholar
  3. 3.
    Schneider AB (1990) Radiation-induced thyroid tumors. Endocrinol Metab Clin North Am 19:495–508PubMedGoogle Scholar
  4. 4.
    Schneider AB, Ron E, Lubin J, Stovall M, Gierlowski TC (1993) Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. J Clin Endocrinol Metab 77:362–369PubMedCrossRefGoogle Scholar
  5. 5.
    Kerber RA, Till JE, Simon SL, Lyon JL, Thomas DC, Preston-Martin S, Rallison ML, Lloyd RD, Stevens W (1993) A cohort study of thyroid disease in relation to fallout from nuclear weapons testing. JAMA 270:2076–2082PubMedCrossRefGoogle Scholar
  6. 6.
    Reiners C (1993) Radioiodtherapie. Indikation, Durchführung und Risiken. Dt Ärztebl 90:2996–3003Google Scholar
  7. 7.
    Franceschi S, Boyle P, Maisonneuve P, La Vecchia C, Burt AD, Kerr DJ, MacFarlane GJ (1993) The Epidemiology of Thyroid Carcinoma. Critical Reviews in Oncogenesis 4:25–52PubMedGoogle Scholar
  8. 8.
    Schröder S (1993) Histological classification of thyroid tumours: a review. Exp Clin Endocrinol 101:1–6Google Scholar
  9. 9.
    TNM-Klassifikation maligner Tumoren (1997) (Hrsg) Wittekind Ch, Wagner G, 5. Auflage, Springer-VerlagCrossRefGoogle Scholar
  10. 10.
    Schröder S, Dralle H, Rehpenning W, Böcker W (1987) Prognosekriterien des papillären Schilddrüsenkarzinoms. Langenbecks Arch Chir 371:263PubMedCrossRefGoogle Scholar
  11. 11.
    Hedinger CE (1993) Probleme der Klassifizierung von Schilddrüsentumoren. Ihre Bedeutung für Prognose und Therapie. Schweiz Med Wschr 123:1673–1681PubMedGoogle Scholar
  12. 12.
    Reiners C, Hüfner M (1987) Nachsorge des papillären, follikulären und onkozytären Schilddrüsenkarzinoms. In: Schilddrüsenmalignome. Diagnostik, Therapie und Nachsorge (Hrsg) Börner W, Reiners Chr; Schattauer-Verlag, Stuttgart: p 159–183Google Scholar
  13. 13.
    Cooper DS, Schneyer CR (1990) Follicular and Hurthle cell carcinoma of the thyroid. Endocrinol Metab Clin North Am 19:577–591PubMedGoogle Scholar
  14. 14.
    Wahl RA, Vietmeier P, Hübner K, Simon D (1990) Undifferenzierte C-Zell-Karzinome. In: Diagnostische und operative Strategien bei endokrinen Erkrankungen (eds) Junginger Th, Beyer J, pmi-Verlag, Frankfurt a.M. p 263–289Google Scholar
  15. 15.
    Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K, Sugawara M (1993) Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 3:93–99PubMedCrossRefGoogle Scholar
  16. 16.
    Tiemann M, Menke AOH, Parwaresch R (1993) Pathogenesis, morphology and molecular genetics of non-Hodgkin’s lymphomas of the thyroid gland. Exp Clin Endocrinol 101:33–38Google Scholar
  17. 17.
    Reiners C, Stuschke M (1996) Schilddrüse. In: Strahlentherapie — Radiologische Onkologie (Hrsg) Scherer E, Sack H, Springer Verlag Heidelberg 401–423Google Scholar
  18. 18.
    Goretzki PE, Witte J, Ohmann C, Stallmann C, Röher HD (1993) On the significance of lymph-node metastases of differentiated thyroid carcinoma on tumor recurrence and patient survival (a quantitative approach by meta-analysis and multivariate analysis of retrospective studies). Exp Clin Endocrinol 101:118–123Google Scholar
  19. 19.
    Byar DP, Green SB, Dor P, Williams D, Conon J, van Gilse HA, Mayer M, Sylvester RJ, van Glabbeke M (1979) A prognostic index for thyroid carcinoma. A study of the EORTC thyroid cancer cooperative group. Europ J Cancer 15:1033–1041Google Scholar
  20. 20.
    Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A (1990) Survival discriminants for differentiated thyroid cancer. Am J Surg 160:344–347PubMedCrossRefGoogle Scholar
  21. 21.
    Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM (1991) Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome [see comments]. Mayo Clin Proc 66:11–22PubMedCrossRefGoogle Scholar
  22. 22.
    DeGroot LJ, Kaplan EL, McCormick M, Straus FH (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71: 414–424PubMedCrossRefGoogle Scholar
  23. 23.
    Mazzaferri EL, Jhiang SM (1994) Long-term Impact of Initial Surgical and Medical Therapy on Papillary and Follicular Thyroid Cancer. Amer J Med 97:418–428PubMedCrossRefGoogle Scholar
  24. 24.
    Samaan NA, Schultz PN, Hickey RC (1988) Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67:801–805PubMedCrossRefGoogle Scholar
  25. 25.
    Samaan NA, Schultz EN, Hickey RC (1992) Well-differentiated Thyroid Carcinoma and the Results of Various Modalities of Treatment. A retrospective Review of 1599 Patients. J Clin Endocrinol Metab 75:714–720PubMedCrossRefGoogle Scholar
  26. 26.
    Thoresen SO, Akslen LA, Glattre E, Haldorsen T, Lund EV, Schoultz M (1989) Survival and prognostic factors in differentiated thyroid cancer — a multivariate analysis of 1055 cases. Br J Cancer 59:231–235PubMedCrossRefGoogle Scholar
  27. 27.
    Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V (1992) Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 164:658–661PubMedCrossRefGoogle Scholar
  28. 28.
    Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1994) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057Google Scholar
  29. 29.
    Reiners C (1992) Nuklearmedizinische Diagnostik des hypofunktionellen Strumaknotens. Nuklearmediziner 15:15–23Google Scholar
  30. 30.
    Reinwein D, Benker G, Windeck R, Eigler FW, Leder LD, Mlynek ML, Creutzig H, Reiners C (1989) Erstsymptome bei Schilddrüsenmalignomen: Einfluß von Alter und Geschlecht in einem Iodmangelgebiet. Erfahrungen an 1116 Patienten. Dtsch Med Wochenschr 114:775–782PubMedCrossRefGoogle Scholar
  31. 31.
    Rüschoff J, Hofstädter F (1997) Wertigkeit der Schilddrüsenpunktionszytologie zur Selektion verdächtiger Knoten. Onkologe 3:16–21CrossRefGoogle Scholar
  32. 32.
    Dralle H (1993) Metaanalyis of thyroid cancer risk in patients with cold thyroid nodules and multinodular goiter. Exp Clin Endocrinol 101:109–117Google Scholar
  33. 33.
    Arnholdt H (1993) Intraoperative frozen section examination of thyroid tumours. Exp Clin Endocrinol 101:7–10CrossRefGoogle Scholar
  34. 34.
    Hüfner M, Reiners C (1987) Thyroglobulin and Thyroglobulin Antibodies in the Follow-up of Thyroid Cancer and Endemic Goiter. Thieme Verlag Stuttgart — New YorkGoogle Scholar
  35. 35.
    Reiners C. Schilddrüsenkarzinom. In: Lüthgens M, Schlegel G (Hrsg) Tumormarkersystem CEA-TPA. TumorDiagnostik Verlag Leonberg, p 175, 191Google Scholar
  36. 36.
    Frilling A (1997) Genetisches Screening in Familien mit multipler endokriner Neoplasie Typ 2. Onkologe 3:38–42CrossRefGoogle Scholar
  37. 37.
    Deutsche Gesellschaft für Chirurgie (1996) Leitlinien der Therapie maligner Schilddrüsentumoren. Mitteil Dtsch Ges Chirurg 3Google Scholar
  38. 38.
    Witte J, Goretzki PE, Röher HD (1997) Chirurgie der differenzierten Schilddrüsenkarzinome. Onkologe 3:22–27CrossRefGoogle Scholar
  39. 39.
    Gimm O, Dralle H (1997) Diagnostik und Therapie sporadischer und familiärer medullärer Schilddrüsenkarzinome. Onkologe 3:32–37CrossRefGoogle Scholar
  40. 40.
    Tisell LE, Hansson G, Jansson S (1989) Surgical treatment of medullary carcinoma of the thyroid. Horm Metab Res Suppl 21:29–31PubMedGoogle Scholar
  41. 41.
    Moley JF, Wells SA, Dilley WG, Tisell LE (1994) Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 114:1090–1095Google Scholar
  42. 42.
    Scheumann GFW, Seeliger H, Pichlmayr R, Wegener G (1997) Chirurgische Therapieoptionen bei anaplastischen Schilddrüsenkarzinomen. Onkologe 3:43–47CrossRefGoogle Scholar
  43. 43.
    Deutsche Gesellschaft für Nuklearmedizin (1997) Leitlinie zur Radioiodtherapie bei differenzierten (papillären, follikulären) Schilddrüsenkarzinomen. AWMF Online 1997Google Scholar
  44. 44.
    Farahati J, Reiners C (1997) Postoperative Radioiodtherapie bei differenzierten Schilddrüsenkarzinomen. Onkologe 3:28–31CrossRefGoogle Scholar
  45. 45.
    Rösler H, Birrer A, Lüscher D, Kindser J (1992) Langzeitverläufe beim differenzierten Schilddrüsenkarzinom. Schweiz Med Wschr 122:1843–1857PubMedGoogle Scholar
  46. 46.
    Sautter-Bihl ML (1997) Hat die perkutane Strahlentherapie einen Stellenwert in der Behandlung des Schilddrüsenkarzinoms? Onkologe 3:48–54CrossRefGoogle Scholar
  47. 47.
    Farahati J, Reiners C, Stuschke M, Müller SP, Stüben G, Sauerwein W, Sack H (1996) Differentiated thyroid cancer — Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 77:172–180PubMedCrossRefGoogle Scholar
  48. 48.
    Leisner B, Degelmann G, Dirr W, Kanitz W, Büll U, Langhammer W, Lissner J, Pabst HW (1982) Behandlungsergebnisse bei Sturma maligna 1960–1980. DMW 107:1702–1707CrossRefGoogle Scholar
  49. 49.
    Müller-Gärtner HW, Brazac HT, Rehpenning W (1991) Prognostic indices for tumor relapse and tumor mortality in follicular thyroid carcinoma. Cancer 67: 1903–1911CrossRefGoogle Scholar
  50. 50.
    Simpson WJ, Panzarella T, Carruthers JS, Gospodarowicz MK, Sutcliffe SB (1988) Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 14:1063–1075PubMedCrossRefGoogle Scholar
  51. 51.
    Philips P, Hanzen C, Andry G, Van Houtte, Frülling J (1993) Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 19:399–404Google Scholar
  52. 52.
    Tubiana M, Hadda E, Schlumberger M, Hill C, Rougier P, Sarrazin D (1985) External radiotherapy in thyroid cancers. Cancer 55:2062–2071PubMedCrossRefGoogle Scholar
  53. 53.
    Jensen MH, Davis RK, Derrick L (1990) Thyroid cancer: a computer-assisted review of 5287 cases. Otolaryngol Head Neck Surg 102:51–65PubMedGoogle Scholar
  54. 54.
    Rougier P, Parmentier C, Laplanche A (1983) Medullary thyroid carcinoma: prognostic factors and treatment. Int J Radiat Oncol Biol Phys 9:161–169PubMedCrossRefGoogle Scholar
  55. 55.
    Scheumann GFW, Wegener G, Dralle H (1990) Radikale chirurgische Intervention mit konventioneller Radiatio versus multimodalem Therapieschema beim undifferenzierten Schilddrüsenkarzinom. Wien Klin Wochenschrift 102:271–273Google Scholar
  56. 56.
    Levendag PC, De Porre PM, van Putten WLJ (1993) Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 26:125–128PubMedCrossRefGoogle Scholar
  57. 57.
    Junor EJ, Paul J, Reed NS (1992) Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 18:83–88PubMedGoogle Scholar
  58. 58.
    Kim JH, Leeper RD (1987) Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Int J Radiat Oncol Biol Phys 26: 125–128Google Scholar
  59. 59.
    Sauerwein W, Reiners C, Lederbogen S (1996) Kombinierte Strahlen-Chemotherapie beim anaplastischen Schilddrüsenkarzinom. In: Usadel KH, Weinheimer B (Hrsg) Schilddrüse 1995. Walter de Gruyter Verlag Berlin — New York 1996, p 401–408Google Scholar
  60. 60.
    Tennvall J, Tallroth E, El Hassan A (1990) Anaplastic thyroid carcinoma. Acta Oncol 29:1025–1028PubMedCrossRefGoogle Scholar
  61. 61.
    Glick JH, Kim K, Earle J, O’Connell MJ (1995) An ECOG randomized Phase III trial of CHOP vs. CHOP + radiotherapy for intermediate grade early stage non-Hodgkin’s lymphoma. Proc ASCO 14:391Google Scholar
  62. 62.
    Miller TP, Dahlberg S, Cassady JR, Carlin S, Chase E, Fisher RI (1996) Three cycles of CHOP plus radiotherapy is superior to eight cycles of CHOP alone for localized intermediate and high grade non-Hodgkin’s lymphoma. A Southwest Oncology Group study. Proc ASCO 15:411Google Scholar
  63. 63.
    Doria R, Jekel JF, Cooper DL (1993) Thyroid Lymphoma. Cancer 73:200–206CrossRefGoogle Scholar
  64. 64.
    Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C (1996) Degree of Thyrotropin Suppression as a Prognostic Determinant in Differentiated Thyroid Cancer. J Clin Endocrinol Metab 81:4318–4323PubMedCrossRefGoogle Scholar
  65. 65.
    Keil I, Hesse J, Höffken K (1997) Nachsorge von malignen Schilddrüsentumoren nach abgeschlossener Primärtherapie. Onkologe 3:59–63CrossRefGoogle Scholar
  66. 66.
    Benker G, Sauerwein W, Reiners C, Olbricht Th, Reinwein D (1990) Die Struma maligna: Möglichkeiten der Chemotherapie. In: Diagnostische und operative Strategien bei endokrinen Erkrankungen (Hrsg) Junginger Th, Beyer J, pmi-Verlag, Frankfurt a.M.p 270–275Google Scholar
  67. 67.
    Raue F (1997) Chemotherapie bei Schilddrüsenkarzinomen: Indikation und Ergebnisse. Onkologe 3:55–58CrossRefGoogle Scholar
  68. 68.
    Schlumberger M, Parmentier C, Delisle MJ, Couette JE, Droz JP, Sarrazin D (1991) Combination therapy for anaplastic giant cell thyroid carcinoma. Cancer 67: 564–566PubMedCrossRefGoogle Scholar
  69. 69.
    Simon D, Köhrle J, Schmutzler C, Mainz K, Reiners C, Röher HD (1996) Redifferentiation therapy of differentiated thyroid carcinoma with retinoic acid: basics and first clinical results. Exp Clin Endocrinol Diabetes 104, Suppl 4:13–15Google Scholar
  70. 70.
    Berding G, Hüfner M, Georgi P (1992) Thyreoglobulin 131J-Ganzkörperszintigraphie und Risikofaktoren in der Nachsorge des differenzierten Schilddrüsenkarzinoms. Nuklearmedizin 31:32–37PubMedGoogle Scholar
  71. 71.
    Cavalieri RR (1996) Nuclear Imaging in the Management of Thyroid Carcinoma. Thyroid 6:485–492PubMedCrossRefGoogle Scholar
  72. 72.
    van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM (1990) Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 212:395–400PubMedCrossRefGoogle Scholar
  73. 73.
    Raue F, Frank-Raue K, Winter J (1990) Klinik, Diagnostik und Nachsorge des C-Zellkarzinoms. In: Diagnostische und operative Strategien bei endokrinen Erkrankungen (Hrsg) Junginger Th, Beyer J, pmi-Verlag, Frankfurt a.M. p 276–282Google Scholar
  74. 74.
    Briele B, Hotze A, Kropp J, Bockisch A, Overbeck B, Grünwald F, Kaiser W, Biersack HJ (1991) Vergleich von 201T1 und 99mTc-MIBI in der Nachsorge des differenzierten Schilddrüsenkarzinoms. Nuklearmedizin 30:115–124PubMedGoogle Scholar
  75. 75.
    Ramanna L, Waxman A, Braunstein G (1991) Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med 32:441–446PubMedGoogle Scholar
  76. 76.
    Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultmann T, Palmedo H, Ruhlmann J, Kozak B, Biersack HJ (1996) Flourine-18 flourodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23:312–319PubMedCrossRefGoogle Scholar
  77. 77.
    Reiners C, Müller StP (1993) Bildgebende Verfahren beim C-Zellkarzinom der Schilddrüse. In: Beyer J, Junginger Th, Lehnert K, Walgenbach S (Hrsg) Diagnostische und chirurgische Aspekte bei endokrinen Erkrankungen. SympoMed Verlag, München.p 213–217Google Scholar
  78. 78.
    Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD (1997) Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyoid Carcinoma. N Engl J Med 337:888–896PubMedCrossRefGoogle Scholar
  79. 79.
    Gottlieb JA, Stratton Hill C (1975) Adriamycin (NSC 123 127) therapy in thyroid carcinoma. Cancer Chemother Rep 6:283–296Google Scholar
  80. 80.
    Burgess MH, Stratton Hill C (1978) Chemotherapy in the management of thyroid cancer. In. Thyroid cancer (Hrsg) Greenfield L. D. Palm Beach, Florida. CRC Press, p 33Google Scholar
  81. 81.
    Shimaoka K, Schoenfeld DA, Dewys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160PubMedCrossRefGoogle Scholar
  82. 82.
    Scherübl H, Raue F, Ziegler R (1990) Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 116:21–23PubMedCrossRefGoogle Scholar
  83. 83.
    Tennvall J, Tallroth E, el Hassan A, Lundell G, Akerman M, Biorklund A, Blomgren H, Lowhagen T, Wallin G (1990) Anaplastic thyroid carcinoma. Doxorubicin, hyperfractionated radiotherapy and surgery. Acta Oncol 29:1025–1028PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • C. Reiners
  • M. Stuschke

There are no affiliations available

Personalised recommendations